Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Autolus Therapeutics plcNASDAQ: AUTL
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 502.5% from a year ago
Net receivables stood at $86.26M at the end of Q1 FY2026, up 502.5% from a year earlier and up 13.8% from the prior quarter. Over 3 fiscal years it compounded at +37.8% a year.
Context
- Net receivables amounted to 16.4% of total assets at the end of Q1 FY2026, up 14.4 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +502.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 75.79M USD
- Year-over-year change
- +57.1%
- 4-year CAGR
- +477.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.79M | +57.1% |
| FY2024 | 2024-12-31 | 48.24M | +4507.4% |
| FY2023 | 2023-12-31 | 1.05M | -96.4% |
| FY2022 | 2022-12-31 | 28.98M | +42511.8% |
| FY2021 | 2021-12-31 | 68K | — |
Net Receivables vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's Mar 2026 net receivables of $86.26M is the 2nd highest of the 10 companies compared; the peer median is $1.3M.
- Its year-over-year change of +502.5% is the 2nd highest of 8, against a peer median of -41.0%.
- Net receivables amounts to 16.4% of total assets for AUTL, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $218.9M | +8.1% | +77.8% | 13.0% | |
| Mar 2026 | $86.26M | +502.5% | +37.8% | 16.4% | |
| Mar 2026 | $15.05M | -41.0% | +12.9% | 5.2% | |
| Mar 2026 | $4M | +99900.0% | — | 2.8% | |
| Mar 2026 | $2.36M | -13.8% | -13.9% | 1.6% | |
| Mar 2026 | $1.3M | — | — | 0.3% | |
| Mar 2026 | $704K | -70.7% | -71.2% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -5.1% | 0.0% | |
| Mar 2026 | $0 | -100.0% | -68.5% | 0.0% | |
| Peer median (excluding AUTL) | $1.3M | -41.0% | -9.5% | 0.3% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 310.34M | 382.44M | 239.57M | 227.38M | 104.13M |
| Short-term Investments | 0 | 0 | 0 | 360.64M | 196.58M |
| Net Receivables | 68K | 28.98M | 1.05M | 48.24M | 75.79M |
| Inventory | 0 | 0 | 0 | 4.14M | 33.21M |
| Other Current Assets | 27.83M | 2.02M | 26.05M | 5.32M | 4.93M |
| Total Current Assets | 346.95M | 425.77M | 275.3M | 660.93M | 435.92M |
| Property, Plant & Equipment (Net) | 52.32M | 58.42M | 95.65M | 105.05M | 128.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 65K | 0 | 0 | 12.37M | 19.81M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 2.08M | 3.06M | 3.24M | 3.56M |
| Other Non-current Assets | 6.23M | 4.01M | 1.36M | 1.13M | 1.28M |
| Total Non-current Assets | 58.61M | 64.5M | 100.08M | 121.8M | 153.15M |
| Total Assets | 405.56M | 490.27M | 375.38M | 782.73M | 589.07M |
| Account Payables | 431K | 531K | 103K | 1.97M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 0 | 14.57M |
| Tax Payables | 0 | 0 | 0 | 3.59M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 160K | 10.57M | 15.29M | 23.66M | 55.79M |
| Total Current Liabilities | 28.55M | 46.37M | 44.74M | 60.74M | 73.44M |
| Long-term Debt | 47.02M | 0 | 0 | 0 | 270.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 128K | 126.02M | 171.26M | 245.03M | 477K |
| Total Non-current Liabilities | 63.69M | 145.23M | 219.17M | 294.66M | 337.5M |
| Total Liabilities | 92.24M | 191.6M | 263.91M | 355.4M | 410.94M |
| Common Stock | 4K | 8K | 8K | 12K | 12K |
| Retained Earnings | (521.34M) | (670.18M) | (878.56M) | (1.1B) | (1.39B) |
| Accumulated OCI | (8.45M) | (38.9M) | (28.99M) | (29.17M) | (5.36M) |
| Other Stockholders Equity | (1) | 118K | 118K | 118K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 313.32M | 298.67M | 111.47M | 427.33M | 178.13M |
| Total Debt | 68.01M | 24.26M | 52.97M | 52.63M | 351.59M |
| Net Debt | (242.32M) | (358.18M) | (186.6M) | (174.75M) | 247.45M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.